RxDoctor Payments DataLook up a doctor →

Lorraine Calvert, NP

Adult Health · Indianapolis, INNPI 1730166778

Payments from drug & device makers

$7,738in general payments, 2019–2025

Across 410 payments — averaging $18.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$1K
  • Lilly USA, LLC$840
  • Amgen$545
  • Corcept Therapeutics$503
  • AstraZeneca$382
  • Medtronic$382
  • plus $4K from 40 others

What the payments were for

  • Food & beverage$7,726100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,738 in reported general payments places this provider in the 95th percentile of 391 adult health providers in Indiana.

See all adult health providers in Indiana

Medicare billing

Part B allowed, 2024
$508,099
Medicare patients
254
Services billed
33,517

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide108$146,669
MounjaroTirzepatide108$134,839
ForteoTeriparatide27$116,185
Teriparatide49$109,043
TymlosAbaloparatide11$54,033
JardianceEmpagliflozin42$49,683
Tresiba Flextouch U-200Insulin Degludec21$44,761
TrulicityDulaglutide23$39,175
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog39$34,764
FarxigaDapagliflozin Propanediol17$27,389
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/728$27,222
Tresiba Flextouch U-100Insulin Degludec25$18,591
HumalogInsulin Lispro38$14,257
Lantus SolostarInsulin Glargine,hum.Rec.Anlog90$13,777
NovologInsulin Aspart47$13,738

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Forteo, Trulicity, Humalog$840$304,455196 claims
Novo NordiskOzempic, Novolog$237$160,408155 claims
Radius Health, Inc.Tymlos$335$54,03311 claims
Boehringer IngelheimJardiance$87$49,68342 claims
AstraZenecaFarxiga$382$27,38917 claims
MerckJanuvia$15$9,17413 claims
AbbVieSynthroid$245$8,32398 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$181$1,039165 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 391 adult health providers in Indiana.

Other adult health in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →